Plain-English translation of NCT02595255 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study follows children aged 3 to 14 who are being treated for cancer or certain other conditions. Researchers will measure a hormone called Antimüllerian Hormone (AMH) — which reflects egg reserve in girls — before treatment starts, right after treatment ends, and then regularly for years afterward. The goal is to understand whether this hormone measurement can predict which children might have fertility problems later in life.
Some cancer treatments can damage a child's reproductive system and affect their ability to have biological children as adults. Currently, doctors don't have a reliable early warning sign to identify which children are at highest risk. This study aims to discover whether checking this hormone level could help doctors spot problems early and offer fertility preservation options to families who need them.
You likely qualify if…
You likely don't qualify if…
You would have blood tests done at the start of treatment, at the end of treatment, and then during follow-up visits — yearly for the first three years, then every two years after that. Each visit includes hormone blood tests and information about puberty development and menstrual cycles (if applicable). There are no experimental medications or procedures; the study only involves standard blood draws and monitoring, making it a straightforward way to help doctors learn how to better protect children's future fertility.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Belgium